Effect of nutritional support on glucose control

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 10, Issue 2, 2007, Pages 210-214

  Seematter, Gerald ^a   Tappy, Luc ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Adiponectin thiazolidinediones; AMP kinase; Carnitylpalmitoyl transferase 1; Fructose

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADIPONECTIN; FRUCTOSE; GLUCOSE TRANSPORTER 4; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; SORBITOL; XYLITOL;

BLOOD GLUCOSE MONITORING; CALORIC INTAKE; CRITICALLY ILL PATIENT; ENTERIC FEEDING; ENZYME ACTIVATION; EXERCISE; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTENSIVE CARE; LIPOGENESIS; MACRONUTRIENT; METABOLIC STRESS; MOLECULAR MECHANICS; NONHUMAN; NUTRITIONAL SUPPORT; OBESITY; PARENTERAL NUTRITION; PROTEIN EXPRESSION; REVIEW; TREATMENT OUTCOME;

BLOOD GLUCOSE; CALORIC RESTRICTION; CRITICAL ILLNESS; DIETARY CARBOHYDRATES; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MULTIENZYME COMPLEXES; MUSCLE, SKELETAL; NUTRITIONAL SUPPORT; PROTEIN-SERINE-THREONINE KINASES;

EID: 33846883014     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/MCO.0b013e3280147711     Document Type: Review

References (53)

1. Malmberg K, Ryden L, Efendic S. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1996; 26:57-65.
2. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352-360.
3. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354:449-461. This paper extends the initial observation of these authors [4] to medical ICU patients. The results obtained are largely at odds with the initial report, and show no or a questionable benefit of maintaining normoglycemia in these patients.
4. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345:1359-1367.
5. Szabo Z, Hakanson E, Maros T, et al. High-dose glucose-insulin-potassium after cardiac surgery: a retrospective analysis of clinical safety issues. Acta Anaesthesiol Scand 2003; 47:383-390.
6. Pittas AG, Siegel RD, Lau J. Insulin therapy and in-hospital mortality in critically ill patients: systematic review and meta-analysis of randomized controlled trials. J Parenter Enter Nutr 2006; 30:164-172. A good update on clinical trials addressing the effects of maintaining near-normal glycemia in ICU patients.
7. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005; 115:2277-2286. This report documents a beneficial effect of high insulin on endothelial cell function.
8. Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulin. Diabetes 2006; 55:1096-1105. This important paper documents, in an animal model, that lowering glycemia and high insulin levels per se exerts beneficial effects on several organs.
9. Stumvoll M, Meyer C, Mitrakou A, et al. Important role of the kidney in human carbohydrate metabolism. Med Hypotheses 1999; 52:363-366.
10. Mithieux G. The new functions of the gut in the control of glucose homeostasis. Curr Opin Clin Nutr Metab Care 2005; 8:445-449.
11. Chioléro R, Revelly JP, Tappy L. Energy metabolism in sepsis and injury. Nutrition 1997; 13 (Suppl):45S-51S.
12. Kahn BB. Lilly lecture 1995. Glucose transport: pivotal step in insulin action. Diabetes 1996; 45:1644-1654.
13. Revelly J-P, Tappy L, Martinez A, et al. Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med 2005; 33:2235-2240. This study provides evidence for increased nonoxidative glucose disposal and lactate production in ICU patients.
14. Minehira K, Bettschart V, Vidal H, et al. Effect of carbohydrate overfeeding on whole body and adipose tissue metabolism in humans. Obesity Res 2003; 11:1096-1103.
15. Minehira K, Vega N, Vidal H, et al. Effect of carbohydrate overfeeding on whole body macronutrient metabolism and expression of lipogenic enzymes in adipose tissue of lean and overweight humans. In J Obes Relat Metab Disord 2004; 28:1291-1298.
16. Jessen N, Goodyear LJ. Contraction signaling to glucose transport in skeletal muscle. J Appl Physiol 2005; 99:330-337. Provides an update on how exercise and AMPK contribute to glucose homeostasis.
17. Rose AJ, Richter EA. Skeletal muscle glucose uptake during exercise: how is it regulated? Physiology 2005; 20:260-270. Provides an update on how exercise and AMPK contribute to glucose homeostasis.
18. Gelfand RA, Matthews DE, Bier DM, et al. Role of counterregulatory hormones in the catabolic response to stress. J Clin Invest 1984; 74: 2238-2248.
19. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002; 5:551-559.
20. Bavenholm PN, Pigon J, Saha AK, et al. Fatty acid oxidation and the regulation of malonyl-CoA in human muscle. Diabetes 2000; 49:1078-108
21. Ruderman NB, Saha AK. Metabolic syndrome: adenosine monophosphate- activated protein kinase and malonyl coenzyme. Obesity 2006; 14 (Suppl. 1):25S-33S. Excellent review depicting the potential role of AMPK as a master metabolic regulator.
22. Winder WW. Intramuscular mechanisms regulating fatty acid oxidation during exercise. Adv Exp Med Biol 1998; 441:239-248.
23. Yoon MJ, Lee GY, Chung JJ, et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor (alpha). Diabetes 2006; 55:2562-2570. This paper gives evidence of the effects of adiponectin on both AMPK and PPARs.
24. Shulman JI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106:171-176.
25. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8:1288-1295.
26. Shibata R, Sato K, Pimentel DR, et al. Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. Nat Med 2005; 11:1096-1103. This study shows, in an experimental model, that adiponectin may protect against oxidative damage.
27. Wang AY, Hickman IJ, Richards AA, et al. High molecular weight adiponectin correlates with insulin sensitivity in patients with hepatitis C genotype 3, but not genotype 1 infection. Am J Gastroenterol 2005; 100:2717-2723. Documents the plasma adiponectin concentration in various acute diseases, and discusses its potential metabolic role in acute disorders.
28. Petit JM, Minello A, Jooste V, et al. Decreased plasma adiponectin concentrations are closely related to steatosis in hepatitis C virus-infected patients. J Clin Endocr Metab 2005; 90:2240-2243. Documents the plasma adiponectin concentration in various acute diseases, and discusses its potential metabolic role in acute disorders.
29. Kaser S, Moschen A, Kaser A, et al. Circulating adiponectin reflects severity of liver disease but not insulin sensitivity in liver cirrhosis. J Int Med 2005; 258:274-280. Documents the plasma adiponectin concentration in various acute diseases, and discusses its potential metabolic role in acute disorders.
30. Onsson JR, Moschen AR, Hickman IJ, et al. Adiponectin and its receptors in patients with chronic hepatitis. J Hepatol 2005; 43:929-936. Documents the plasma adiponectin concentration in various acute diseases, and discusses its potential metabolic role in acute disorders.
31. Reeds DN, Yarasheski KE, Fontana L, et al. Alterations in liver, muscle, and adipose tissue insulin sensitivity in men with HIV infection and dyslipidemia. Am J Physiol Endocrinol Metab 2006; 290:E47-E53. Documents the plasma adiponectin concentration in various acute diseases, and discusses its potential metabolic role in acute disorders.
32. Vigouroux C, Maachi M, Nguyen TH, et al. Serum akipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17:1503-1511.
33. Tong Q, Sankale JL, Hadigan CM, et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003; 88:1559-1564.
34. Tsuchihashi H, Yamamoto H, Maeda K, et al. Circulating concentrations of adiponectin, an endogenous lipopolysaccharide neutralizing protein, decrease in rats with polymicrobial sepsis. J Surg Res 2006; 134:348-353. This study demonstrates that adiponectin levels decrease in an animal model of sepsis.
35. Blumer RM, van Thien H, Ruiter AF, et al. Adiponectin and glucose production in patients infected with plasmodium falciparum. Metab Clin Exp 2005; 54:60-66. Documents the plasma adiponectin concentration in various acute diseases, and discusses its potential metabolic role in acute disorders.
36. Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006; 574:41-53.
37. Bandyopadhyay GK, Yu JG, Ofrecio J, et al. Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 2006; 55:2277-2285. Shows that thiazolodinediones exert regulatory effects on AMPK.
38. Lessard SJ, Chen ZP, Watt MJ, et al. Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 2006; 290:E251-E257. Shows that tiazolodinediones exert regulatory effects on AMPK.
39. Konrad D, Rudich A, Bilan PJ, et al. Troglitazone causes acute mitochondrial membrane depolarisation and an AMPK-mediated increase in glucose phosphorylation in muscle cells. Diabetologia 2005; 48:954-966. Shows that tiazolodinediones exert regulatory effects on AMPK.
40. Lee S, Kim W, Kang KP, et al. Agonist of peroxisome proliferator-activated receptor-gamma, rosiglitazone, reduces renal injury and dysfunction in a murine sepsis model. Nephrol Dial Transplant 2005; 20:1057-1065. Reviews the potential beneficial effects of thiazolidinediones in critically ill patients.
41. Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005; 23:393-399. Reviews the potential beneficial effects of thiazolidinediones in critically ill patients.
42. Bergheim I, Luyendyk JP, Steele C, et al. Metformin prevents endotoxin-induced liver injury after partial hepatectomy. J Pharmacol Exp Ther 2006; 316:1053-1061. This study documents the beneficial effects of metformin in preventing endotoxin-induced damage.
43. Cherrington AD. Control of glucose uptake and release by the liver in vivo. Diabetes 1999; 48:1198-1214.
44. Rigalleau V, Beauvieux M, Gallis J, et al. Effects of hyperglycemia on glucose metabolism before and after oral glucose ingestion in normal men. Am J Physiol Endocrinol Metab 2006; 290:E1198-E1204.
45. Rusavy Z, Macdonald IA, Sramek V, et al. Glycemia influences on glucose metabolism in sepsis during hyperinsulinemic clamp. J Parenter Enter Nutr 2005; 29:171-175.
46. Chen SS, Torres-Sanchez CJ, Hosein N, et al. Time course of the hepatic adaptation to TPN: interaction with glycogen depletion. Am J Physiol Endocrinol Metab 2005; 288:E163-E170.
47. Chen SS, Torres-Sanchez CJ, Hosein N, et al. Route-dependent effect of nutritional support on liver glucose uptake. Am J Physiol Regul Int Comp Physiol 2005; 289:R1319-R1327.
48. Lê K-A, Tappy L. Metabolic effects of fructose. Curr Opin Clin Nutr Metab Care 2006; 9:469-475. An update on the potentially detrimental effects of fructose in the long term.
49. Elia M, Ceriello A, Laube H, et al. Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes: a systematic review and meta-analysis. Diabetes Care 2005; 28:2267-2279. This metaanalysis supports the use of diabetic formulas to lower plasma glucose in patients with diabetes fed enterally.
50. Tappy L, Schwarz JM, Schneiter P, et al. Effects of isoenergetic glucose-based or lipid-based parenteral nutrition on glucose metabolism, de novo lipogenesis, and respiratory gas exchanges in critically ill patients. Crit Care Med 1998; 26:860-867.
51. Schwarz JM, Schutz Y, Froidevaux F, et al. Thermogenesis in men and women induced by fructose vs glucose added to a meal. Am J Clin Nutr 1989;49:667-674.
52. Mayer K, SchaeferMB, Seeger W. Fish oil in the critically ill: from experimental to clinical data. Curr Opin Clin Nutr Metab Care 2006; 9:140-148. Excellent review of the effects of fish oil in critically ill patients.
53. Tappy L, Berger MM, Schwarz JM, et al. Metabolic effects of parenteral nutrition enriched with n-3 polyunsaturated fatty acids in critically ill patients. Clin Nutr 2006; 25:588-595. This study shows, in a small group of ICU patients, that administration of fish oil does not significantly lower glycemia during TPN.